Major European venture firms launched the European Life Science Coalition (ELSC) with backing from Invest Europe and members managing over €24 billion to address structural underinvestment in life‑sciences VC across the continent. The coalition aims to advocate for better institutional allocations, more harmonized capital markets, and policy fixes rather than act as an investment vehicle. ELSC leaders—including Sofinnova Partners, Novo Holdings and Omega Funds—said the effort targets ecosystem‑level changes such as increasing institutional allocations and reducing financing fragmentation that drives European biotechs to list and scale in the U.S. The group highlighted Europe’s current 7% share of global life‑sciences VC versus 63% for the U.S. If successful, the campaign could increase late‑stage financing and local IPO capacity, easing exits and reducing the need for European startups to migrate to the Nasdaq for growth capital.